Equities
Health CareMedical Equipment and Services
  • Price (EUR)27.70
  • Today's Change0.000 / 0.00%
  • Shares traded7.21k
  • 1 Year change-35.73%
  • Beta0.1916
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

  • Revenue in EUR (TTM)250.54m
  • Net income in EUR10.01m
  • Incorporated2018
  • Employees1.46k
  • Location
    Stratec SeGewerbestr. 37BIRKENFELD 75217GermanyDEU
  • Phone+49 708279160
  • Fax+49 70 827916999
  • Websitehttps://www.stratec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Detection Technology Oyj-100.00bn-100.00bn203.72m464.00--2.76----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
BICO Group AB194.42m-67.91m206.41m828.00--0.8285--1.06-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Onward Medical NV0.00-35.15m207.97m99.00--7.67-----1.09-1.090.000.60790.00----0.00-66.40-55.70-79.20-61.60-------79,513.95----0.4855---34.62---10.40--32.59--
Medistim ASA47.17m8.76m222.95m152.0025.416.3720.424.735.555.5529.8722.121.130.74617.483,599,204.0021.0522.9325.5328.5279.1278.2518.5820.642.75--0.018175.257.0010.06-8.9112.720.03314.87
Tristel Plc50.40m7.80m252.12m213.0032.606.4522.815.000.1350.1350.87140.68180.98121.815.74--15.189.3217.7510.7680.0880.7515.4711.093.04--0.1532109.3516.459.8945.469.9910.1319.53
Nyxoah SA5.08m-52.98m271.45m147.00--2.59--53.41-1.72-1.720.1663.040.03660.55692.3034,618.53-38.20-23.73-42.88-25.9861.7562.42-1,042.52-1,469.594.95-45.270.1822--40.99---38.39--100.58--
COLTENE Holding AG257.11m13.29m322.98m1.19k24.353.0015.621.262.062.0639.8916.731.271.386.06198,668.906.5510.4811.7018.7464.9062.685.177.470.861910.180.342179.94-9.133.54-54.05-6.81-7.72-7.79
Guerbet SA826.24m32.76m332.46m2.92k10.480.85333.720.40242.512.5166.4230.820.81280.54935.56282,958.603.031.404.961.8678.5876.023.731.821.163.850.507357.824.30-0.0993158.05-12.615.23-10.07
Stratec SE250.54m10.01m336.77m1.46k33.631.4811.501.340.82360.823620.6118.740.56051.275.32164,609.702.247.072.858.2027.0427.324.009.700.92693.860.401140.81-4.636.88-55.293.30-2.16-7.68
Synektik SA143.84m19.49m343.24m164.0017.627.7615.252.399.929.9273.2522.521.8426.956.41--24.9815.0939.9723.8326.8224.8813.5511.001.4945.180.109--39.8235.9061.3656.0850.89--
IVF Hartmann Holding AG164.62m18.99m377.27m298.0019.862.4814.962.297.357.3563.7258.840.87883.148.52502,947.4010.147.2912.068.9055.2153.2911.548.303.95--0.005852.16-1.792.0934.951.49-14.8326.82
medmix AG516.49m-1.94m383.85m2.70k--0.76466.190.7432-0.05-0.0511.3511.300.47783.405.58180,474.00-0.09962.06-0.12272.4932.5836.38-0.20854.161.062.210.436167.701.991.40-97.41-64.3612.01--
Ion Beam Applications SA465.75m7.85m399.73m1.84k49.104.2720.390.85820.26890.268915.993.090.77212.152.70234,517.101.301.556.014.3234.1935.231.692.380.63723.770.399264.8318.6710.74-250.40---8.06--
CellaVision AB63.63m12.97m441.60m228.0034.066.6626.676.946.306.3030.9132.190.78491.917.263,233,162.0015.9915.3018.4518.2466.9969.0320.3819.982.151,358.860.044110.185.9413.1710.128.0030.458.45
RaySearch Laboratories AB (publ)100.90m15.11m458.75m414.0039.118.4412.774.555.105.1034.0923.650.60235.513.293,005,152.009.021.2913.691.8891.0690.5714.972.551.27108.610.370669.0021.1610.26243.060.7648-1.31--
Data as of Nov 21 2024. Currency figures normalised to Stratec Se's reporting currency: Euro EUR

Institutional shareholders

31.66%Per cent of shares held by top holders
HolderShares% Held
Brown Capital Management LLCas of 30 Jun 20241.08m8.86%
Invesco Advisers, Inc.as of 31 Dec 2023609.88k5.02%
Union Investment Privatfonds GmbHas of 25 Oct 2024400.00k3.29%
Juno Investment Partnersas of 31 Dec 2023363.00k2.99%
Threadneedle Asset Management Ltd.as of 31 Dec 2023346.29k2.85%
The Vanguard Group, Inc.as of 06 Nov 2024251.42k2.07%
Janus Henderson Investors UK Ltd.as of 30 Sep 2024212.85k1.75%
Comgest SAas of 31 Jul 2024203.73k1.68%
Candriam Belgium SAas of 30 Sep 2024198.89k1.64%
UBS Asset Management Switzerland AGas of 30 Sep 2024186.60k1.54%
More ▼
Data from 31 Jul 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.